V
4.46
0.51 (12.91%)
Previous Close | 3.95 |
Open | 3.99 |
Volume | 1,897,928 |
Avg. Volume (3M) | 740,944 |
Market Cap | 198,498,992 |
Price / Sales | 13.54 |
Price / Book | 16.31 |
52 Weeks Range | |
Earnings Date | 6 Nov 2024 |
Operating Margin (TTM) | -1,145.05% |
Diluted EPS (TTM) | -3.14 |
Total Debt/Equity (MRQ) | 128.59% |
Current Ratio (MRQ) | 3.23 |
Operating Cash Flow (TTM) | -109.35 M |
Levered Free Cash Flow (TTM) | -32.02 M |
Return on Assets (TTM) | -47.31% |
Return on Equity (TTM) | -136.87% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Verastem, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.5
Analyst Consensus | 1.0 |
Insider Activity | -5.0 |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -1.5 |
Average | -1.50 |
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Core |
% Held by Insiders | 0.83% |
% Held by Institutions | 59.93% |
52 Weeks Range | ||
Price Target Range | ||
High | 13.00 (RBC Capital, 191.48%) | Buy |
Median | 9.00 (101.79%) | |
Low | 7.00 (HC Wainwright & Co., 56.95%) | Buy |
Average | 9.67 (116.82%) | |
Total | 3 Buy | |
Avg. Price @ Call | 3.95 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 19 Dec 2024 | 7.00 (56.95%) | Buy | 4.44 |
18 Oct 2024 | 7.00 (56.95%) | Buy | 2.96 | |
Mizuho | 19 Dec 2024 | 9.00 (101.79%) | Buy | 4.44 |
RBC Capital | 18 Oct 2024 | 13.00 (191.48%) | Buy | 2.96 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
CALKINS DANIEL | - | 4.05 | -93 | -382 |
GAGNON ROBERT E. | - | 4.44 | -130 | -577 |
PATERSON DAN | - | 4.44 | -183 | -813 |
STUGLIK BRIAN M | - | 4.44 | -334 | -1,483 |
Aggregate Net Quantity | -740 | |||
Aggregate Net Value ($) | -3,254 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 4.28 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
CALKINS DANIEL | Officer | 24 Dec 2024 | Sell (-) | 28 | 3.90 | 109 |
CALKINS DANIEL | Officer | 20 Dec 2024 | Sell (-) | 65 | 4.19 | 272 |
PATERSON DAN | Officer | 19 Dec 2024 | Sell (-) | 183 | 4.44 | 813 |
STUGLIK BRIAN M | Director | 19 Dec 2024 | Sell (-) | 334 | 4.44 | 1,483 |
GAGNON ROBERT E. | Director | 19 Dec 2024 | Sell (-) | 130 | 4.44 | 577 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |